Skye Bioscience Rallies; Holiday Week Puts Focus on Tuesday
Skye Bioscience finished Friday up 16.03% at $0.8293. Shares of the obesity drug developer swung through the week after a safety committee signed off on the next dose group in its nimacimab trial. The stock dropped on Monday, Tuesday and Thursday, climbed Wednesday, and rose again heading into the long weekend. Timing could be key. U.S. stocks aren’t open on Saturday, and with Nasdaq shut for Memorial Day on Monday, May 25, investors will have to wait for regular trading to pick back up Tuesday to react to the news.